DaVita Inc. (DVA) Earnings Call Transcript & Summary
February 13, 2024
Earnings Call Speaker Segments
Nic Eliason
executiveThanks for joining us for the call covering our fourth quarter, and we're glad you remain interested in what our company is doing. Nic Eliason here — I serve as Group Vice President of Investor Relations — and with me on today's call are Javier Rodriguez, who is our CEO, and Joel Ackerman, our CFO. I want to point out that we might share forward-looking statements on this call as defined under the federal securities laws. Known and unknown risks and uncertainties apply to each of those statements, and those factors could make actual results come out materially different from what the forward-looking statements describe. If you want more information about these risks and uncertainties, take a look at the press release for our fourth quarter earnings and the filings we've made with the SEC, which include our latest annual report on Form 10-K, every quarterly report on Form 10-Q filed afterward, and any other documents we subsequently file with the SEC. The information we currently have forms the basis for our forward-looking statements, and we have no intention and take on no obligation to revise those statements, unless the law says we must. We also want to note that some non-GAAP financial measures will come up during this call. You can find a reconciliation of those non-GAAP measures against the closest comparable GAAP financial measures in the earnings press release we furnished to the SEC, which is also posted on our website. At this point, I'll hand things over to Javier Rodriguez.
Javier Rodriguez
executiveThank you, Nic, and I appreciate everyone being on today's call. Looking back over the last 12 months, the 2023 results we posted made clear how resilient this business is, and they also showed a few of the initial gains from the multiyear effort we've made to strengthen our platform. The outside pressures of recent years ended up leaving us in a better place, and because we keep putting money into our people, our systems and our capabilities, we feel we are strongly positioned for what lies ahead. We entered 2024 carrying real momentum, with less of the risk and uncertainty that have marked the last several years. On this call, I'll walk through our 2023 results and our 2024 guidance, give our yearly update on integrated kidney care and pick up briefly where we left off on GLP-1 drugs. Before any of that, though, I want to open the call the way we always do, with the clinical highlights. For over two decades, we have worked to put community first and company second; that means we are devoted both to delivering excellent care and to giving back. During 2023, our teammates put in more than 42,000 hours serving their communities, our best year on record and progress toward our cumulative target of 125,000 hours by 2025. A number of our extraordinary teammates also gave their own time to push forward our aim of building awareness around kidney disease; we just finished our 2023 health tour, a program of mobile health screenings and kidney care education that supports local communities nationwide. Right now, kidney disease affects 15% of the U.S. population, and frequently it remains undiagnosed and untreated until symptoms turn severe. Our mobile health tour was built to help spot risk factors that can lead to chronic kidney disease, and it screened for obesity, diabetes, high blood pressure and a family history of kidney disease. Over 2 months on the road, our bus covered 17,000 miles and provided free screenings in 48 communities spanning 8 states. To make this tour possible, over 300 of our teammates gave 1,200 hours volunteering in service to their local communities; this work is a great illustration of pairing our commitment to service with our continuing dedication to raising awareness about early detection and prevention of kidney disease. Now to our performance. For the full year 2023, adjusted operating income, adjusted EPS and free cash flow all finished well above the guidance we gave at the start of the year. For context, I think it helps to look back at how we progressed across the year. We started 2023 in an uncertain climate and laid out in our guidance the assumption that volume and labor pressures would persist through 2023; at the same time, we were building and carrying out a range of initiatives aimed at offsetting some of the financial headwinds we faced. As the year went on, we saw encouraging data points early on, and those eventually became consistent positive trends. Those better patterns, along with solid operational results and the beneficial effect from actions we took, produced 20% growth in adjusted operating income compared with a year earlier, 28% growth in adjusted EPS, and brought our leverage ratio back into the target range. Let me offer 3 points for extra detail. Starting with volume: we began 2023 facing a 2% growth headwind tied to annualizing excess mortality from the prior year. From that point, each successive COVID surge proved smaller in size and carried lower mortality. Meanwhile, we managed to deliver 4 straight quarters of year-over-year gains in new patient admits. Putting those pieces together, 2023 brought the first rise in patient census since COVID began, with volume roughly flat versus a year earlier, finishing at the upper end of our guidance range. Next, labor results during 2023 surpassed 2022; we reduced dependence on contract labor faster than we had expected and strengthened staffing across our centers; on the flip side, teammate turnover stayed high, consistent with robust health care labor markets. Going forward, better retention and training costs offer a chance for gains in coming years. Third, apart from those patterns, we generated solid operational results via our distinctive platform and capabilities. In particular, we put money into revenue operations to secure lasting gains in collections; that added $3.50 in revenue per treatment across the full year while trimming over 12 days from U.S. days sales outstanding. Beyond that, we carried out cost-saving efforts tied to pharmaceutical spend and further consolidated our facility footprint. Lastly, we surpassed yearly profitability goals for integrated kidney care, which I'll discuss in greater depth shortly. In short, we started 2024 with greater visibility and confidence than at any point since COVID emerged in 2020. Our capacity to invest in people, process, and systems, even with the operational and financial difficulties of recent years, has set us up well for what lies ahead. With that said, let me shift to our value-based care segment, which we'll refer to as integrated kidney care, or IKC. We've repeatedly encouraged investors to evaluate this business annually instead of concentrating on quarterly results. This is a good moment to stop and consider how IKC has performed and what lies ahead. Broadly, we judge IKC results using 3 main metrics: one, total medical expense and patients within our IKC programs, which reflects growth; two, our clinical performance, or how effectively we lower total medical costs; and three, per member per month spending on our model of care and G&A, which signals cost management. I'll go through each with somewhat more detail. First, total medical expense for patients in our IKC programs climbed to $4.6 billion, amounting to roughly 30% growth year-over-year, and covers care for 58,000 patients as of year-end, a 38% rise from 2022. When it comes to our traditional value-based care offerings, we stay disciplined and put profitable expansion first. Looking at 2024, we anticipate more than 25% growth for both total medical expense and covered lives. Next, our care model has demonstrated it works — it helps patients live more healthily and brings medical costs down, which shows up in a net savings rate running a bit ahead of what we projected. The biggest factor there is the decrease in hospitalizations compared with the prior year, particularly when it comes to readmissions. That depends on our joint efforts, with care teams and physician partners working together, to stop acuity from climbing and to serve our most complex and vulnerable patients. And last, our per member per month costs keep falling thanks to program expansion and better fixed cost leverage. During 2023, per member per month costs dropped 7%. We anticipate a further decrease of roughly 15% in per member per month costs during 2024. Thanks to all this, we beat our forecast for the 2023 adjusted operating loss, and we think we're still on track to reach breakeven or better by 2026. Past those core metrics, we can dig deeper into how we performed by looking at 3 main parts of our IKC business: Special Need Plans, our value-based care portfolio that centers mostly on Medicare Advantage patients, and the CKCC demonstration project serving our Medicare fee-for-service patients.
Javier Rodriguez
executiveLooking at that portfolio, following years of funding and steady annual gains in cost reduction, our MA contracts along with Special Need Plans have at last become profitable. Remember that CKCC, the third piece, accounts for roughly 50% of the census in our value-based care operation. We make adjustments in response to CMS changes and keep refining our care model; we anticipate this program turning profitable around the 2026 timeframe. Before diving into 2024, a brief word on GLP-1. To be clear, our thinking remains unchanged from the prior earnings call. Soon after that call, results came out for the SELECT clinical trial. As we expected, that trial verifies particular cardiovascular advantages for those with obesity and cardiovascular disease, among them a 20% decrease in all-cause mortality. Up next in the near term is the FLOW study, which we expect will show efficacy across multiple end points, among them a slowing of chronic kidney disease progression. As a reminder, any such efficacy the FLOW study may show is already built into our GLP-1 base case, which mirrors a net neutral effect on dialysis volume growth as adoption increases across the coming decade. Moving to 2024. We are issuing guidance of 10% growth in adjusted operating income and 9% growth in adjusted EPS, representing the midpoint of our guidance range for each respective metric; this factors in our assumptions of a more predictable operating environment, ongoing returns from what we invested in revenue cycle and additional strides in IKC. Such guidance illustrates how resilient our business is and our capacity, even with outside pressures, to deliver high-quality care while producing robust financial results. Let me address several drivers behind our forecast. First, 2024 adjusted operating income will gain from the full year effect of favorable developments in 2023, among them annualizing revenue cycle improvements, our shift to MIRCERA and savings tied to consolidating our centers. Second, as mentioned, we are showing progress in our IKC business and still anticipate reaching breakeven by 2026. And last, adjusted earnings per share will gain from our share repurchase program, offset by other items beneath the OI line such as other losses, increased interest expense and a higher effective tax rate. As we move into 2024, we have a strong opportunity to pursue operating improvements that set DaVita further apart in kidney care. I will now hand things to Joel so he can cover our financial performance and outlook in greater depth.
Joel Ackerman
executiveThanks, Javier. In the fourth quarter, adjusted operating income came to $415 million, and adjusted earnings per share were $1.87. Because of how well we performed during the quarter, we finished slightly above the upper bound of the revised guidance range for the full year that we discussed on the Q3 call. What drove us past our expectations for the quarter was mainly prior period development within the special needs programs in our IKC business, along with growth in revenue per treatment stemming from ongoing gains in revenue cycle management. Within the U.S. dialysis segment, treatments per day during the fourth quarter came in flat compared with the third quarter. Keep in mind that mistreatment rates run seasonally higher during winter months, and that was offset by better day of week mix than we saw in the third quarter. Revenue per treatment rose by roughly $6 from one quarter to the next. Roughly half of that came from ordinary quarterly swings. The rest of the increase came in equal parts from ongoing gains in revenue cycle management and the usual fourth quarter seasonality tied to a higher acutes mix and reimbursement for flu vaccines. Adjusted patient care cost per treatment rose $13 on a sequential basis, mostly because of seasonality, which includes greater benefits expense and ongoing investment in our teammates. That sequential rise was larger than what Q4 typically brings but matched what we told you to expect on our Q3 earnings call. Turning to our IKC business, adjusted operating results fell $39 million sequentially, mainly because of the timing of shared services revenue that was recognized in Q3, largely from arrangements dating to 2022. On top of that, during Q4 we recognized an additional $55 million in shared savings revenue tied to Medicare Advantage value-based care arrangements for plan year 2023. We recognized revenue for the 2023 arrangements sooner than we had expected, and that happened because several revenue recognition hurdles cleared earlier than anticipated; otherwise, this revenue would have been recorded in 2024. Given that, we now expect our recognition of shared savings revenue for Medicare Advantage contracts in 2024 and later to generally line up with the plan year in which it is earned. That said, updates to our estimates will probably keep occurring within each planned year and afterward, until final reconciliation. The $55 million in shared savings revenue recognized in 2023 has been left out of our adjusted operating income, since it reflects earnings beyond what 2023 would have produced without the change. International adjusted operating income fell $18 million quarter-over-quarter. The biggest piece of that sequential shift came from a rise in bad debt reserves. Moving to capital structure. During the fourth quarter, we bought back 2.9 million shares, and since 2024 began, we have bought back another 1.5 million shares. We closed 2023 with a 0 balance on our revolving credit facility, and our leverage ratio edged down to 3.15x consolidated EBITDA, which sits under the midpoint of our target leverage range. Strong free cash flow came partly from the ongoing reduction of our U.S. For dialysis DSOs, the quarter closed at 54 days — that's a reduction of 3 days versus the prior quarter and 12 days lower than where we stood at the close of 2022. Now let's walk through specifics of our 2024 guidance. For the full year, we're guiding adjusted operating income to $1.825 billion to $1.975 billion, which works out to 9.6% growth year-over-year at the midpoint; that sits above our longer-run expectation of 3% to 7% growth in adjusted operating income, and the drivers are stronger revenue per treatment growth in typical, coming from our investments in revenue cycle management, plus cost savings in our nonlabor patient care costs thanks to annualization of MIRCERA and savings tied to our footprint. For more detail, allow me to walk through the 3 primary drivers of U.S. dialysis growth compared with 2023. One, we're expecting treatment volume growth of 1% to 2%. That comes from continued growth in new patient admissions that matches pre-pandemic averages, partly offset by mortality that we anticipate will stay a bit above pre-COVID levels. Two, we're anticipating revenue per treatment growth of 2.5% to 3%. Roughly 2/3 of that growth stems from rate increases. The other third of the expected increase comes mainly from annualizing the revenue cycle management improvements achieved in 2023. Three, we're expecting adjusted patient care cost per treatment to rise 2.5% to 3%. We still anticipate wages rising at rates exceeding pre-COVID levels. Offsetting savings include fixed cost leverage as treatment volume expands and annualization of 2023 cost savings initiatives, among them our switch to MIRCERA for anemia management and our center consolidation work. Let me note a couple of other items to assist your thinking on U.S. dialysis; we're expecting adjusted depreciation and amortization to fall by roughly $10 million to $15 million, which is a notable shift from historical increases of about $20 million each year. That reflects the delayed payoff of our sustained, multiyear push to raise capital efficiency. On policy matters, we aren't anticipating spending the $50 million to $60 million tied to ballot measures that past election years would typically have involved. For IKC, our guidance bakes in an adjusted operating income loss of roughly $50 million. That mirrors our expectation of continued growth in total medical spend and covered lives across our IKC programs, better shared savings performance, and additional fixed cost leverage, as Javier laid out in his earlier remarks. Within our international business, we've built into guidance continued growth in adjusted operating income of about $20 million year-over-year. Below the OI line, we're expecting losses of roughly $60 million, mostly stemming from our share of losses at Mozarc, the kidney products co-investment we hold with Medtronic. We're anticipating interest expense of $100 million to $110 million per quarter during the first half of the year, then $130 million to $140 million per quarter during the second half. The rise here stems from the fact that our 2% interest rate caps expired at midyear. We're looking at an adjusted effective income tax rate in the range of 24% to 26%. When it comes to free cash flow, our expectation is $900 million to $1.15 billion, which works out to roughly 125% of adjusted net income. In line with how we approach capital over the long term, we intend to put the overwhelming majority of that free cash flow toward capital-efficient growth whenever those opportunities are available, or, if not, to give capital back to shareholders via share repurchases. We expect to finish the year inside our long-term target leverage ratio range of 3 to 3.5x. That brings my prepared remarks for today to a close. Operator, please open the call for Q&A.
Dean Rosales
analystDean Rosales here, filling in for Justin. I'd like to ask about your Medicare risk businesses. I'm curious what trends you're observing there as we move through 2023. Then, regarding special needs products specifically, exactly how many members do you have in those? And what revenue do those products bring in? Also, could you address what you've observed on the cost side so far this year, and then Q4 in particular?
Joel Ackerman
executiveThank you, Dean. On the Medicare Advantage risk side, what I'd point out is that it's key to understand the ESRD population differs from the wider MA population. Certain trends you may be noticing among other payers — which we of course monitor very closely — don't necessarily hold true for our population. Let me point to 3 things. To start, these patients' needs and the medical costs they carry look quite different from a given population, because these patients are highly acute. That's one. Next, I'd add that reimbursement for this population operates differently, with a distinct reimbursement rate that appears in both the preliminary and the final rule; and third, the coding changes affecting the wider MA population don't extend to the ESRD population; so given all that — I believe it's early for us to truly have a complete picture of what 2023 holds. Even so, we feel fairly good regarding where our net savings landed, on the SNP side as well as the Medicare Advantage population within our value-based care. As for a bit of the cleanup, we have roughly 3,000 members in our SNP products, and on revenue, it sits somewhere above $300 million.
Pito Chickering
analystWhen we look at the 2024 guidance, you're building in a $50 million loss for IKC. Could you remind us what that figure was for 2023? Also, in the script I believe you mentioned IKC revenue growth of 25% along with a PMPM reduction of 15%. My assumption would have been that those metrics would move you from a loss to a gain in 2024, so if you could help bridge that; and then I think there's a shift happening from cash accounting to accrual accounting. For you guys, that appears to be quite a significant change. What I'd like to know is what gives you confidence that accrual makes sense at this point?
Joel Ackerman
executiveYes. So there's a lot packed in there, Pito. Let me attempt to work through this in logical sequence; so first, regarding revenue accounting. What — in the past, we didn't record revenue until we felt comfortable that our share of the shared savings could be reasonably estimated. And that held true for our MA population as well as our Medicare fee-for-service population, the CKCC program. For the SNP product, we've always accounted for it using, to borrow your phrase, an accrual method. What we're discussing is a change in the timing of when we become comfortable with those estimates; and you asked the reason why; it really comes down to 3 things. First, we adjusted some contract wording, which lets us know sooner who is attributed to us. That's the first thing. Next, the data reaches us faster, and that obviously means we can run certain calculations earlier. Then there's the third piece: because of everything we've learned along the way, our actuarial models have improved. Put those three together, and we now feel confident we can make a reasonable projection of the portion of shared savings revenue owed to us, which in the end turns into revenue within the plan year. That's what explains the shift in estimates. Now, on the question about 2023: for 2024, our guidance points to a $50 million loss. On a non-GAAP basis, 2023 came in at a $94 million loss. Regarding that $94 million figure, you should know it contains income generated by value-based care offerings tied to plan year '23—stemming from the estimate adjustment I brought up earlier—plus income from that same product line during 2022. Therefore, to view 2023 in a way that's closer to an apples-to-apples comparison with '24, you'd want to subtract roughly $25 million, $25 million, perhaps $30 million to get things more comparable; and then, what else did you ask? A PMPM question was part of it.
Pito Chickering
analystRight. So once you remove that $25 million to $30 million, you're left with a loss of $94 million. In the script, I believe your guidance pointed to 25% growth inside IKC, followed by a 15% decrease in PMPM for '24. Given that, my assumption would be those gains plus those cost cuts should have produced operating income rather than an operating loss. So how do we reconcile those growth figures and those expense reduction figures with still arriving at a $50 million loss?
Joel Ackerman
executiveYeah. A few points. To begin with, let me be clear that the change in estimate I mentioned applies solely to the Medicare Advantage business. CKCC is still sufficiently new that we don't feel comfortable projecting the savings within the plan year, so nothing there has shifted. Regarding what you asked, the savings we're talking about relate only to our model of care and our G&A. It isn't what you would refer to as the MLR in a health plan operation. For us, it isn't comparable. Next, there were some — 2023 included a substantial amount of positive period development, especially within the SNP business, and we aren't projecting that it repeats. That gives us one more adjustment, which I believe helps bridge the question of why we aren't reaching profitability next year — or this year, in '24.
Pito Chickering
analystThen regarding treatment growth, what we see is normalized growth of 70 bps in 4Q. During the third quarter, you had 50 bps of growth. For the fourth quarter, is the main factor new patients? Is it reduced mortality? Also, if you shut a center and its patients move to a different center, does that count as organic growth at the new location? Is the old location simply your discontinued ops, even though the patients themselves don't really alter the numbers?
Joel Ackerman
executiveYes; so regarding that last one, no. When a patient goes from one clinic to another, that doesn't appear as growth of any kind anywhere. That patient remains ours; as far as volume growth goes, I'd describe Q4 versus Q3 as essentially flat, with treatments per day flat; and that really reflects a slight census decrease, which happens often in Q4, balanced out by an improved treatment mix per day, meaning more Monday, Wednesday, Fridays; fewer Tuesdays, Thursdays. So Q4, I would say, was a flat volume quarter-over-quarter.
Joanna Gajuk
analystJoanna Gajuk here, covering for Kevin at the moment. To begin, my first question just picks up where the volume conversation left off and — seems like it was roughly flat quarter to quarter, though I believe year over year it rose by under 1%. Meanwhile your '24 outlook calls for volume expansion of 1% to 2%. So how exactly do you get there, particularly reaching the upper bound of 2%? What makes you confident that you can achieve that level of volume growth across the year?
Joel Ackerman
executiveYes. Thank you, Joanna. Let me begin with the point that census is the largest single factor driving volume on a year-over-year basis. And keep in mind that census accumulates as the year progresses; so when you examine the '23 growth, essentially flat, it was weighed down by census having fallen throughout 2022 and only beginning to build during '23. Thus much of that 0 in 2023 reflects the annualization of 2022's adverse effects. Turning to '24, I would truly separate it into 2 pieces. The first is new-to-dialysis admissions, which we have seen building throughout 2023. And we are at ease that this growth rate has returned to where it stood before COVID. The — the factor keeping us from returning to what you would call a 2% figure from pre-COVID times, or that would be the top of the range, is that mortality keeps running above its pre-COVID level. It has fallen considerably from its COVID peak, yet it remains somewhat elevated versus a normal pre-COVID year, and bear in mind that mortality fluctuated during pre-COVID years, mainly because of how severe the flu season was. So if you combine a more typical new-to-dialysis admit expectation with a marginally negative mortality expectation, that is how we arrive at the 1% to 2%.
Joanna Gajuk
analystThen one more question about the guidance, I suppose. You discussed what you expect for revenue per treatment. So to be precise, could you walk through the components, I suppose, behind that? How much, I suppose, comes from commercial rate increases? And I suppose in the prior quarter, you said certain bigger contracts were coming up for renewal. So any detail on those rate increases you're observing there? And within that as well, your mix, commercial against government, and then particularly MA, where you sit on the MA mix.
Javier Rodriguez
executiveGreat. I'll take that one, Joanna. A few points, since I think beneath those questions, there's typically — there's something out of the ordinary in the payer dynamics, and let me begin by saying, no, we're in a typical period. And naturally, we're working to ensure our rates capture the inflationary pressures we're facing. To your direct question about what percent of that — what portion comes from rate, approximately two-thirds of the increase will be rate and one-third the rest. A significant part of that is the annualization of the reimbursement, operational improvements we saw in 2023, and what remains is mix. As you've observed, our mix is leaning toward MA somewhat above the market. So our MA mix ended the quarter at roughly 52%, and we anticipate that figure being a couple of points greater at the close of '24, so somewhere in the 54%, 55% range, depending on open enrollment.
Joanna Gajuk
analystNow, regarding that commercial plan you brought up, with certain bigger plans coming up for renewal, is there anything new on what kind of rate hikes you're observing?
Javier Rodriguez
executiveOn the commercial side — as far as those negotiations go, we won't get into details. What we keep seeing is that folks with commercial coverage appreciate their private insurance, and our commercial mix is holding roughly steady. So there's nothing to share on that front. And naturally, that's factored into the RPT guidance we provided to you.
Albert Rice
analystI can't let this call wrap up without posing a single GLP-1 query. So, according to your prepared remarks, for the FLOW study you're expecting effectiveness across several end points, which includes slowing CKD for digression. My sense is that's basically where the market stands. Given the analysis you've provided, which seems to have gained real traction among the financial community, I was curious: is there anything at all that might emerge from the FLOW study — at least within the high probability range — that would cause you to reconsider? It looks as though you've addressed nearly everything you anticipate in your analysis, but I'm asking whether something could shift you toward being more optimistic, or less optimistic, regarding how all this will affect your business?
Javier Rodriguez
executiveThank you for asking, A.J; and as you're aware, during the prior quarter, we delivered something of a dissertation on GLP-1 that generated considerable discussion. Ultimately, we of course aimed to ensure that our shareholders and others were thoroughly informed about it. And my view is that although an unusual surprise remains possible, since you never want to claim the odds are 0, it's highly, highly improbable that our range failed to capture what will most likely unfold. So that means — ultimately, we foresee a net neutral effect on dialysis volume across the coming 10 years. And we made plenty of probabilistic adjustments and weighted for how many individuals would take part and all the standard math we covered; and we have no desire to alter our stance whatsoever.
Albert Rice
analystOkay, that's great. Maybe I'll go a different way and ask what assumptions you're making about labor as we move into '24. I get that there's the basic element — what you're expecting on the wage and benefit side for your full-time employees. From what I understand, you ought to still see some benefit from contract labor, at least by annualizing the point at which you're wrapping up the year. And then there's the whole California minimum wage question for health care workers earning low wages. I believe you said you wouldn't be spending on election spending, but I'd like to know what you're factoring in for that and when you think it will start to matter.
Joel Ackerman
executiveSure, A.J., I appreciate that. About staffing expenses for the year, we pinpointed an increase of 2.5% to 3% in the cost of caring for each patient per treatment. Let me break that down. Roughly 50% of it comes from labor, with the rest from other areas. Within that labor piece, we expect about 5% across the year, and California is part of that figure. A few months back, we estimated somewhere between $30 million and $40 million as the net effect once it reaches full deployment, at a count of 20 to 25 for '24. Our rollout has moved a bit quicker than we'd planned. So my guess is the final figure will probably fall within that 25 to 30 range, and our overall number already accounts for it. We're comfortable with patient care costs landing between 2.5% and 3%, even though labor makes up half of that and wages are climbing at 5%, because we're seeing savings from annualizing MIRCERA — both the transition to it and certain clinic footprint moves we made. On top of that, we gain fixed cost leverage by growing volume without opening new centers; many of those remaining expenses stay flat as volume rises and sit under long-term agreements. So even with 5% wage pressure, we believe we can reach that 2.5% to 3% range.
Ryan Langston
analystRyan Langston here, filling in for Gary tonight. Dean mentioned this before, I believe, but let's revisit it — what effect does that elevated Medicare Advantage trend from the latter part of the year have on accruals, not just for '23 but also on your '24 guidance? And Joel, could you tell us again when you expect the final reconciliation with your plan partners to happen?
Joel Ackerman
executiveYeah. So when that final reconciliation occurs is going to vary. It differs from plan to plan. Often it takes 3 or 4 quarters, and ultimately that gets baked into prior period development within the IKC business. As for how some of those costs affected the broader MA population in Q4, well, it's too soon in our view to determine whether that will have an impact on us, but I'd say again that our population differs quite a bit from the broader one. When it comes to 2024, we're watching it closely to see how things unfold, and our range already accounts for it.
Lisa Clive
analystI have just a couple of questions. First, it's been 18 months since the Marietta decision. Your commercial mix and pricing look fairly steady. So I was wondering whether you have any perspective on what that ruling has meant across the last 2 years and whether you anticipate any shifts. Then, to clarify one more thing: given that you don't have to fund a ballot initiative and clearly your wages in California are rising, it seems like a sensible truce with the SEIU. Should we count on that continuing? Or does it only last through this election cycle? Or, obviously, it would be nice for you folks to escape this 2-year cycle of battling ballot initiatives.
Javier Rodriguez
executiveOkay. Thanks, Lisa. Let's begin with Marietta. As we've said before, we haven't observed many employer groups altering benefits, which is truly wonderful. It would be awful if employers denied their employees who have end-stage renal disease that choice. Still, we remain very attentive and, naturally, coordinate with the kidney community and disability groups, since there's a kind of dangerous risk out there that we want to ensure isn't exploited. So the comparison I offer, at a town hall when somebody asks me if I have — why I feel so strongly about it, is like telling someone the lock on your house door is broken, and you say, yes, but nobody has broken in, or very few, and you say, well, you still want to repair it. So from where we sit, it's something the Supreme Court spoke to. It required clarification, and the champions in Congress and others think it should be clarified. Now we simply have to work the process. I also believe, and we've talked about this, that our verification process at admissions has helped, in that we had an instance of an employer group that in fact did apply this, and once they discovered their employees truly lacked a network, they altered their benefits again and essentially went back to a network benefit. So I think sometimes people try out ideas without truly grasping the full ramifications, and in that instance, it turned out well. And so we'll keep devoting a lot of energy to that. Your second question concerned the ballot. Naturally, what we appreciated about it is that we were putting money toward making sure our patients and our teammates didn't endure what we term a very dangerous ballot process, but educating the broader state on how to think about that costs a lot of money. And so we're extremely pleased that, in the end, rather than spending that money on it, our teammates receive the benefit of that. When it comes to whether this is only about the current election cycle, we mentioned 2 election cycles, and that would be a good opportunity to hopefully work through and take another look at our relationship with labor.
Dean Rosales
analystDean here once more, filling in for Justin. I'd like to ask about center closings. Apologies if this has already come up. But what remains to be done on that front? And might you speak to, or perhaps break down, how the center closing flows through to the P&L — that is, revenue against the savings on costs, from reduced fixed costs and efficiencies?
Javier Rodriguez
executiveSure; thanks for raising that. Our expectation for the year is approximately 50 centers either shut down or folded into others, plus around 20 new ones, so a net of 30. On the P&L side, I'm not certain I grasped your question. Would you mind asking it once more?
Dean Rosales
analystBeyond that, just how the various pieces affect the P&L. Could you just address how you folks — a single center shutting down...
Javier Rodriguez
executiveA solid, reasonable lens for this is that you'll see a modest drop in volume tied to patients selecting elsewhere, yet once you set all that aside, those centers are usually inefficient. So the move is to combine the management and the leadership. Then you pick up some reductions on fixed costs, especially rent and medical director fees. So ultimately, that's the source of the savings, an inefficient center with certain fixed expenses that are taken out.
Pito Chickering
analystIf I could just ask a couple of follow-ups here. Regarding what Joanna brought up, how did the commercial mix break down for the quarter? And what's your outlook for 2024?
Javier Rodriguez
executiveThe commercial mix came in at 10.9 for the quarter, and we anticipate it remaining roughly flat.
Pito Chickering
analystOkay, sounds good. And after that, free cash flow conversion came in really strong during '23. Your guidance sits at roughly 54% for '24. Is something shifting when it comes to cash flow conversion, or is it just the DSOs you achieved — what was it, 12 days in '23 — that won't happen again in '24?
Joel Ackerman
executiveYeah. That's exactly right. The DSO reduction in '23 was genuinely remarkable. Looking at '24, free cash flow conversion is still comfortably higher than net income, and 2 factors really account for that. First, purely from a structural standpoint, our CapEx runs below our depreciation and amortization; and the second is share-based comp, stock-based comp; and those 2 items ought to stick around, which explains why, let's say, 125% of net income that we're generating in free cash flow this year, we'd anticipate continuing for a while.
Pito Chickering
analystAlright. Any news regarding AB 290?
Javier Rodriguez
executiveA bit of an update exists. Things are happening with it. Still, when all is said and done, the simplest way to put it might be that no final decision has come from the judge, though some indication was offered; and within that indication, essentially each side gained a few points while each side also gave up a few points, so because of that, the likelihood of an appeal being filed once a final ruling arrives is fairly strong. So then the follow-up question is likely this: if someone were to ask what the financial effect would be, previously we had provided guidance somewhere between $25 million and $40 million; and since fewer individuals remain on the AKF, my sense is that figure will probably come in lower. Something closer to $0 million to $25 million would be a solid range.
Pito Chickering
analystAll right, that's good. So, one more thing before we finish. Let me put the question about closing centers in a different way. What did center liquidation come to at the close of — I believe, during Q4 of '23? And what are you assuming it will be in Q4 of '24?
Joel Ackerman
executiveMy apologies, Pito, were you referring to capacity utilization?
Pito Chickering
analystYeah. I mean, when you consider centers shutting down along with patients returning, plus general center liquidation, how do you finish out '23? And what do you figure that number could reach by the close of '24?
Joel Ackerman
executiveRight. So we're wrapping up the year at roughly 58%; and my expectation is we gain a point, perhaps slightly more, as the year goes on.
Javier Rodriguez
executiveTo give you some context, if we look back to before the pandemic—let's say around 2016, several years ago—we were sitting at roughly 65%. Then, to illustrate how much this whole California situation we've discussed has affected things, California, given how tough it is to operate there, comes in at about 70%, since nobody is opening centers. So all of these costly proposals and bad behavior have taken a toll, and people simply don't want to open centers in that state.
Pito Chickering
analystAnd so, just to satisfy my curiosity, if across a span of multiple years you returned to roughly 65%, would that translate into something like 300 basis points of G&A leverage? And if you could give me a sense of the size of that, it would be great.
Joel Ackerman
executiveYes. Well, the leverage would show up in what we spend on patient care; it wouldn't be in G&A, since a clinic carries a fixed cost that sits within patient care cost. So that's where you'd find it. The most helpful thing I can offer for that calculation, I think, is to consider our patient care cost per treatment figure — we ran at $255 for 2023. Of that, approximately two-thirds is variable and one-third is fixed. So suppose we expanded that volume without constructing as many centers — and let me be clear, we would still need to construct some centers, because although capacity utilization is low, the capacity might not sit precisely where you need it geographically; so based on whatever assumption you adopt there, keeping in mind that one-third of that PCC per treatment is fixed, I believe that gives you all you need to work out what it could be worth.
Javier Rodriguez
executiveAlright. Michelle, thanks, and thanks to everyone for your interest in DaVita. To sum up, we ended the year strongly, and that, along with our 2024 guidance, puts us back on a path to recover our pre-pandemic financial trajectory. We'll keep working hard to deliver strong results, innovate, and most importantly, provide great clinical care for our patients. Thank you all for joining the call. Be well.
Operator
operatorThanks. That wraps up the conference call for today. At this point, you're welcome to disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete DaVita Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to DaVita Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DaVita Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.